The Innovative Medicines Initiative (IMI) adds pain to its agenda

  • Improving the care of patients suffering from acute or chronic pain

There is a very high need for improving health care for the management of pain, which is the scope of this Topic. The Topic consists of three Subtopics, each of which addresses a specific aspect and scientific challenge in this area:

A: Using patient reported outcome measures to improve the management of acute and chronic pain (PROMs)

B: Improving the translatability of pharmacodynamic biomarkers in pain pathways of healthy subjects and preclinical species (BIOM)

C: Improving translation in chronic pelvic pain (CPP)


The overall key impact of the execution of this topic, via its three components as indicated in the subtopics, will be to improve and standardise different patient-centric treatments for the management of acute and chronic pain, ostensibly the most burdensome disease in terms of patient suffering and healthcare costs. In particular, it is anticipated that new tools and methods will pave the way to the identification of improved treatments which are able to reduce both the disease intensity and the risk of chronification of post-surgical and other acute pain conditions, thus assuring a better quality of life for pain patients.


The Innovative Medicines Initiative (IMI) is working to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need. It does this by facilitating collaboration between the key players involved in healthcare research, including universities, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. IMI is a partnership between the European Union (represented by the European Commission) and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations).


You find more info under:

You can register now for the webinar on 07th December, 02.00-04.00 pm CET

In case of further questions, potential applicants should contact the IMI Programme Office (

Go back

  1. Societal Impact of Pain (SIP)
  2. Newsroom
  3. News
  • Register for the SIP Newsletter

    Stay informed about the most important events and news about the Societal Impact of Pain platform.

    subscribe now


Essential cookies are essential for the operation of the website and can therefore not be deactivated.

Cookie information


Statistics cookies allow the collection of anonymous information about how you use our website. They help us to improve your user experience and our content.

Cookie information

External media

External media cookies allow media content to be loaded from external sources. They can also be activated when you visit the website if you encounter blocked media content.

Cookie information